BlackRock, Inc. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
3,615,316 7.800% |
-1,349,703 (-27.18%) |
Filing |
| 2024-12-06 4:28 pm Purchase |
2024-11-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
4,965,019 10.700% |
96,230 (+1.98%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
4,868,789 9.400% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
4,868,789 9.400% |
1,404,202 (+40.53%) |
Filing |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
3,464,587 8.100% |
955,955 (+38.11%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
2,508,632 7.700% |
420,950 (+20.16%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BlackRock Inc. BLK |
2,087,682 6.500% |
2,087,682 (New Position) |
Filing |